IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GIUGLIANO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.382
AS - Asia 1.753
NA - Nord America 1.328
SA - Sud America 200
AF - Africa 49
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.735
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 1.271
US - Stati Uniti d'America 1.232
CN - Cina 504
SG - Singapore 502
IT - Italia 359
HK - Hong Kong 156
VN - Vietnam 152
SE - Svezia 149
BR - Brasile 143
FR - Francia 129
IN - India 118
RU - Federazione Russa 106
GB - Regno Unito 92
BD - Bangladesh 88
NL - Olanda 52
CA - Canada 50
JP - Giappone 50
ES - Italia 46
ID - Indonesia 38
FI - Finlandia 36
IE - Irlanda 31
MX - Messico 30
KR - Corea 29
TR - Turchia 29
CH - Svizzera 26
AR - Argentina 22
PL - Polonia 21
TW - Taiwan 19
BE - Belgio 14
AU - Australia 12
CO - Colombia 11
PH - Filippine 10
CI - Costa d'Avorio 9
EG - Egitto 9
PK - Pakistan 9
CL - Cile 7
GR - Grecia 7
IQ - Iraq 7
LB - Libano 7
NZ - Nuova Zelanda 7
TN - Tunisia 7
PT - Portogallo 6
VE - Venezuela 6
DZ - Algeria 5
IR - Iran 5
JM - Giamaica 5
MY - Malesia 5
RO - Romania 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
AT - Austria 4
EC - Ecuador 4
KE - Kenya 4
MA - Marocco 4
PE - Perù 4
SK - Slovacchia (Repubblica Slovacca) 4
CZ - Repubblica Ceca 3
HN - Honduras 3
HR - Croazia 3
HU - Ungheria 3
KZ - Kazakistan 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
SD - Sudan 3
TH - Thailandia 3
UA - Ucraina 3
BY - Bielorussia 2
IL - Israele 2
LU - Lussemburgo 2
SC - Seychelles 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
GI - Gibilterra 1
GT - Guatemala 1
GU - Guam 1
JO - Giordania 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
NA - Namibia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
SI - Slovenia 1
SR - Suriname 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.735
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.190
Singapore 248
Ashburn 217
Hong Kong 125
San Jose 93
Hefei 88
Milan 86
Dallas 73
Santa Clara 73
Beijing 60
Los Angeles 58
Chandler 57
Council Bluffs 47
Hanoi 45
Boardman 39
Rome 39
New York 37
Bengaluru 35
Ho Chi Minh City 30
Lauterbourg 30
Shanghai 30
Dublin 27
Buffalo 26
Helsinki 25
Hyderabad 24
Jakarta 22
Moscow 21
Tokyo 21
Munich 20
Paris 20
Boston 17
Southend 17
São Paulo 17
Montreal 15
Bologna 14
Chennai 14
Florence 14
Cangzhou 13
London 13
Chicago 12
Guangzhou 12
Toronto 12
Cambridge 11
Madrid 11
Naples 11
Seoul 11
Shenzhen 11
Mexico City 10
Nuremberg 10
Princeton 10
Taipei 10
Abidjan 9
Düsseldorf 9
Gdansk 9
Rio de Janeiro 9
Atlanta 8
Barcelona 8
Buenos Aires 8
Cairo 8
Fuzhou 8
Turin 8
Ann Arbor 7
Brussels 7
Da Nang 7
Denver 7
Hangzhou 7
Istanbul 7
Nanjing 7
Oklahoma City 7
Oldham 7
Santiago 7
Lappeenranta 6
Putnam Valley 6
Quanzhou 6
Roubaix 6
Stockholm 6
Valencia 6
Vancouver 6
Ahmedabad 5
Anacapri 5
Ancona 5
Biên Hòa 5
Bogotá 5
Charlotte 5
Cologne 5
Lanester 5
Portsmouth 5
Rho 5
Seattle 5
Tunis 5
Verona 5
Warsaw 5
Zurich 5
Amsterdam 4
Aracaju 4
Baghdad 4
Brasília 4
Brescia 4
Brooklyn 4
Can Tho 4
Totale 3.470
Salva come PNG Salva come JPEG
Nome #
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 772
Margetuximab for the treatment of HER2-positive metastatic breast cancer 534
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 248
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 241
Evolution of low HER2 expression between early and advanced-stage breast cancer 217
Auto-immune toxiity of Sars-Cov2 vaccine in patients with thymic epithelial tumours: a prospective analysis from the tyme net 213
Bystander effect of antibody-drug conjugates: fact or fiction? 203
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 201
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 195
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 192
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 184
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 183
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 176
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 171
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives 166
HER2-Low Breast Cancer: a New Subtype? 164
Clinical development and current role of margetuximab for the treatment of breast cancer 160
Characterization of low HER2 expressions in de-novo metastatic breast cancer 159
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 157
Antibody–drug conjugates for the treatment of breast cancer 156
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology 148
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 145
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 138
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 136
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases 128
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 123
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 119
PARP Inhibitors for Breast Cancer Treatment 86
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 70
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 63
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort 5
HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era 3
null 3
Postneoadjuvant treatment for triple-negative breast cancer 3
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers 1
Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors 1
Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer 1
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer 1
Emerging treatment landscape of non-muscle invasive bladder cancer 1
Totale 5.867
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.314
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.314
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/2022155 14 10 8 4 7 6 2 20 28 18 16 22
2022/2023429 22 32 48 39 41 41 22 32 49 22 52 29
2023/20241.405 47 47 42 68 110 76 202 162 88 158 192 213
2024/20251.522 166 189 158 160 107 63 34 119 76 129 131 190
2025/20262.327 291 214 266 190 159 115 312 100 225 139 235 81
Totale 5.867